Cerebrotech Appoints CEO and Member of Board of Directors

Cerebrotech Medical Systems, a medical device company developing neurotechnology solutions, has named Carl O’Connell as CEO and appointed John T. Kilcoyne to the company’s Board of Directors. O’Connell and Kilcoyne are seasoned executives with significant experience in the healthcare industry and medical device market. 
 
“Carl and John both bring proven track records of success in the neurosurgery medical device market and we are excited to welcome them,” said Martin Dieck, executive chairman, Cerebrotech Medical Systems. “As Cerebrotech transitions from the R&D phase to commercial expansion, the leadership and industry vision of both Carl and John will be critical for successfully shaping our future.”
 
O’Connell has extensive experience in the fields of neurotechnology, visualization and imaging, with impressive success inspiring organizational improvement and advancing sales and marketing strategies and implementation. He most recently served as president and CEO of Xtant Medical Technologies, and held executive positions with Wright Medical, Stryker Corp. and Carl Zeiss Surgical. O’Connell also provided guidance to GE Healthcare for their neurointerventional imaging business. 
 
Currently heading JenaValve Technology Inc., Kilcoyne was previously CEO and president of one of the first public neurovascular device companies, Micrus Endovascular, which was sold to Johnson & Johnson under his tenure. He successfully led several other device companies, including ReVision Optics and Endonetics, and held senior management positions with Guidant/ACS and Boston Scientific Corp., among others. A strong industry leader, Kilcoyne has served on the Boards of Directors for a number of companies, presently holding a position with Cerus Endovascular.
 
Cerebrotech is planning a U.S. launch of the Cerebrotech Visor System, having gained clearance from the U.S. Food and Drug Administration as an aid in the assessment of fluid volume differences between the cerebral hemispheres in patients undergoing neurologic assessment. The company also has plans to conduct additional clinical studies to obtain regulatory clearances for assessment of brain pathologies including stroke, trauma, swelling and others.
 
O’Connell and Kilcoyne join the company at a critical time, as support for Cerebrotech’s technology continues to grow. Recently, Cleveland Clinic included the Visor System among the Top 10 Medical Innovations of 2019, a list of up-and-coming technologies selected by a panel of Cleveland Clinic physicians and scientists, which comes on the heels of a presentation related to the Visor System at the annual meeting of the Joint Cerebrovascular Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons with the Society of NeuroInterventional Surgery. 
 
Cerebrotech Medical Systems Inc. is a venture capital-backed company dedicated to designing neurotechnology solutions to improve the care of brain-injured patients worldwide. The company is developing and investigating a portable, noninvasive neuro-monitoring device that allows for earlier detection of potentially life-threatening conditions such as large vessel occlusion stroke, cerebral edema, traumatic brain injury, and others. Founded in 2010 and based in Pleasanton, Calif., Cerebrotech’s core intellectual property is licensed exclusively from the University of California at Berkeley. Cerebrotech is backed by: Tri-Star Health Partners, a healthcare-focused venture capital firm; Mountain Group Partners, a life sciences and technology focused venture capital firm; and Neuro Technology Investors, a group of physician investors in the neurology space.